These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 300420)
1. Must labels name the drug? Gursky S J Leg Med (N Y); 1977 Mar; 5(3):17-9. PubMed ID: 300420 [No Abstract] [Full Text] [Related]
2. The package insert and the pharmacist's liability. Simonsmeier LM Am J Pharm Sci Support Public Health; 1977; 149(3):82-9. PubMed ID: 596428 [No Abstract] [Full Text] [Related]
4. The patient package insert and its legal implications. Cook D Leg Med Q; 1980; 4():258-70. PubMed ID: 10258797 [No Abstract] [Full Text] [Related]
5. Package inserts, adverse drug reactions, and the physician's liability. Morrell MX Ration Drug Ther; 1975 Aug; 9(8):1-6. PubMed ID: 1144773 [No Abstract] [Full Text] [Related]
6. The patient medication instruction (PMI) leaflet: regulatory and evidentiary ramifications. Yacura M Spec Law Dig Health Care (Mon); 1986 Mar; 8(1):7-27. PubMed ID: 10276993 [No Abstract] [Full Text] [Related]
7. Enterprise liability for bad outcomes from drug therapy: the doctor, the hospital, the pharmacy, and the drug firm. Furrow BR Spec Law Dig Health Care Law; 1998 Apr; (229):9-69. PubMed ID: 10178162 [No Abstract] [Full Text] [Related]
8. ASHP statement on hospital drug control systems. Am J Hosp Pharm; 1974 Dec; 31(12):1198-207. PubMed ID: 4458439 [No Abstract] [Full Text] [Related]
9. [Rules for the advertising of special preparations? Suggestion for a safe standardization]. Naess K Tidsskr Nor Laegeforen; 1968 Mar; 88(5):347-9. PubMed ID: 5671518 [No Abstract] [Full Text] [Related]
11. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense. Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421 [No Abstract] [Full Text] [Related]
12. From a malpractice lawyer's case book. Ledakovich A Med Times; 1974 Nov; 102(11):203-5. PubMed ID: 4416977 [No Abstract] [Full Text] [Related]
13. A defense of the learned intermediary doctrine. Goetz RB; Growdon KR Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470 [No Abstract] [Full Text] [Related]
14. The variability and quality of medication container labels. Shrank WH; Agnew-Blais J; Choudhry NK; Wolf MS; Kesselheim AS; Avorn J; Shekelle P Arch Intern Med; 2007 Sep; 167(16):1760-5. PubMed ID: 17846395 [TBL] [Abstract][Full Text] [Related]
15. Legal implications of preparing and dispensing approved drugs for unlabeled indications. Podell LB Am J Hosp Pharm; 1983 Jan; 40(1):111-3. PubMed ID: 6823981 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016 [TBL] [Abstract][Full Text] [Related]
17. American Pharmaceutical Association House of Delegates, May 13-18, 1978, Montreal, Quebec, Canada. Report of the Policy Committee on Organizational Affairs. Am Pharm; 1978 Jul; 18(8 Spec No):32-5. PubMed ID: 665505 [No Abstract] [Full Text] [Related]
18. Quality control for pharmacy prepared labels. Davis NM Hosp Pharm; 1989 Dec; 24(12):991-2. PubMed ID: 10296555 [No Abstract] [Full Text] [Related]